JEPQ vs XBI
JPMorgan Nasdaq Equity Premium Income ETF vs SPDR S&P Biotech ETF
- • JEPQ pays a higher dividend yield (10.43%).
Side-by-side metrics
| Metric | JEPQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 10.43% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $37.67B | $8.30B |
YTD return | 6.01% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.76 | 1.09 |
P/E ratio | 32.56 | — |
Last price | $59.38 | $133.66 |
Inception | — | — |
Issuer | JPMorgan | State Street |
JEPQ top holdings
| NVDA | NVIDIA Corp | 7.76% |
| AAPL | Apple Inc | 6.29% |
| GOOG | Alphabet Inc Class C | 6.28% |
| MSFT | Microsoft Corp | 4.91% |
| AMZN | Amazon.com Inc | 4.72% |
| META | Meta Platforms Inc Class A | 2.99% |
| MU | Micron Technology Inc | 2.89% |
| AVGO | Broadcom Inc | 2.78% |
| AMD | Advanced Micro Devices Inc | 2.70% |
| TSLA | Tesla Inc | 2.48% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About JEPQ
JEPQ (JPMorgan Nasdaq Equity Premium Income ETF) is Nasdaq-tilted equity income with options overlay. Managed by JPMorgan, the fund carries $37.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 10.43%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.8% of the portfolio. Real Estate is the fund's largest sector exposure at 0.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.